Chahine L M, Iranzo A, Fernández-Arcos A, Simuni T, Seedorff N, Caspell-Garcia C, Amara A W, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, Oertel W
1Department of Neurology, The University of Pittsburgh, Pittsburgh, PA USA.
Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.
NPJ Parkinsons Dis. 2019 Jan 29;5:2. doi: 10.1038/s41531-018-0073-1. eCollection 2019.
REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson's Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included. Assessments at the screening visit including DAT SPECT imaging, physical examination, cognitive function screen, and questionnaire-based non-motor assessment. The group with DAT binding deficit ( = 49) was compared to those without ( = 26). There were no significant differences in demographic or clinical features between the two groups. When recruiting RBD cohorts enriched for high risk of neurodegenerative disorders, our data support the need for objective biomarker assessments.
快速眼动睡眠行为障碍（RBD）与帕金森病及其他与α-突触核蛋白相关的疾病的发生密切相关。多巴胺转运体（DAT）结合缺陷可预测RBD个体向α-突触核蛋白相关疾病的转化。反过来，确定哪些RBD个体具有DAT结合异常的最高可能性将是有用的。本分析的目的是研究是否存在RBD中DAT缺陷的基本临床预测指标。纳入了被推荐纳入帕金森病进展标志物倡议RBD队列的参与者。筛查访视时的评估包括DAT单光子发射计算机断层扫描（SPECT）成像、体格检查、认知功能筛查和基于问卷的非运动评估。将有DAT结合缺陷的组（n = 49）与无缺陷的组（n = 26）进行比较。两组在人口统计学或临床特征上无显著差异。在招募富含神经退行性疾病高风险的RBD队列时，我们的数据支持进行客观生物标志物评估的必要性。
